Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

NCT06297603 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of the medication retatrutide compared to a placebo in adults with type 2 diabetes and moderate or severe kidney problems who are not well-controlled on basal insulin, with or without metformin and/or SGLT2 inhibitors.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 320 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-03 · est. completion 2026-11

Where 76 sites · Argentina, Brazil, Israel, Mexico, Puerto Rico, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT06297603 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change from Baseline in Hemoglobin A1c (HbA1c) (%)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06297603 ↗